miRNA-34a-5p is a novel biomarker and modulator of the radioresponse in esophageal adenocarcinoma.

miR-34a-5p acts as a radiosensitizer and biomarker, with reduced expression linked to poor treatment response and survival in esophageal adenocarcinoma.

• Why it matters: Improving prediction of treatment resistance and developing targeted therapies are essential to enhance outcomes for EAC patients facing chemoradiotherapy failure.
• What they did: Researchers analyzed cell lines and clinical samples, finding that overexpressing miR-34a-5p increased radiosensitivity by impairing DNA repair and cell cycle progression, while low levels correlated with poor response and prognosis.
• The result: These findings position miR-34a-5p as a promising biomarker and therapeutic target, enabling personalized treatment strategies and potentially improving radiotherapy effectiveness in EAC.